Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

LncRNA gene marker and kit for ovarian cancer clinical diagnosis

A gene marker and kit technology, applied in the field of gene diagnosis, can solve the problem of lack of molecular markers and achieve the effect of improving the accuracy

Inactive Publication Date: 2021-01-19
NANJING FIRST HOSPITAL
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In view of the lack of relatively accurate molecular markers in the clinical diagnosis of ovarian cancer at present, the purpose of the present invention is to overcome the deficiencies of the prior art in the early diagnosis of ovarian cancer, to provide lncRNA gene markers for early diagnosis of ovarian cancer, for the preparation of ovarian cancer clinical diagnostic kits

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • LncRNA gene marker and kit for ovarian cancer clinical diagnosis
  • LncRNA gene marker and kit for ovarian cancer clinical diagnosis
  • LncRNA gene marker and kit for ovarian cancer clinical diagnosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Example 1. Detection of LincROR level in plasma. The patients with plasma samples involved in this study were all patients hospitalized in the Department of Gynecology of Nanjing First Hospital due to pelvic masses, gynecological malignant tumors, and postoperative chemotherapy for ovarian cancer. There were 220 patients in total, including 42 cases of ovarian cancer, After chemotherapy, there were 26 cases of cancer, 38 cases of endometrial cancer, 35 cases of cervical cancer, 23 cases of endometriosis, and 56 cases of benign ovarian cysts, aged 11 to 83 years. The plasma samples of the healthy control group were 30 healthy volunteers randomly selected by the Physical Examination Center of our hospital, aged 38-61 years. This study was approved by the Hospital Ethics Committee, and all subjects gave informed consent, and there was no statistically significant difference in age.

[0015] Use EDTA anticoagulant tubes to collect about 5ml of venous blood from the patient...

Embodiment 2

[0018] Example 2. Application of LincROR in clinical diagnosis of ovarian cancer. The present invention is used to detect the relative expression of LincROR in the plasma of healthy control women of the same age group, ovarian cysts, endometrium cancer, cervical cancer, endometriosis, ovarian cancer and ovarian cancer after chemotherapy, and the detection results show that, The expression level in the plasma of ovarian cancer patients was significantly higher than that of normal people and patients with benign ovarian cysts (3.03±4.35vs 0.31±0.24, 3.03±4.35vs 0.59±0.50, p figure 2 .

[0019] Using the relative expression of lncRNAROR in all samples of the ovarian cancer group and non-ovarian cancer (including ovarian benign cysts and healthy controls) group as the independent variable, and the group as the dependent variable, the comparison of LincROR in the ovarian cancer group and non-ovarian cancer group samples Binary logistic regression was performed on the relative inter...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a long-chain non-coding RNA gene marker LincROR in early diagnosis, prognosis and chemotherapy sensitivity judgment of ovarian cancer. The blood plasma and bloodserum LincROR provided by the invention have excellent diagnostic performance for diagnosing ovarian cancer and non-ovarian cancer (including benign ovarian cyst and health control), can improve theaccuracy, sensitivity and specificity of judgment in ovarian cancer clinical diagnosis and chemotherapy sensitivity by combining with application of the existing tumor marker CA125, and can be developed into a diagnostic kit for early diagnosis of ovarian cancer.

Description

technical field [0001] The invention belongs to the field of gene diagnosis, in particular to lncRNA gene markers for early diagnosis of ovarian cancer. Background technique [0002] Ovarian cancer is one of the most common malignant tumors in my country, and its mortality rate ranks first among gynecological tumors. Due to the non-specific symptoms and signs in the early stage, about 80% of ovarian cancer patients are diagnosed at an advanced stage, and the 5-year overall survival rate is only 35% to 57%. If diagnosed early and treated in time, the 5-year survival rate can reach 90%. CA125 is considered to be the only best marker for early diagnosis of ovarian cancer at present, but screening with CA125 alone has certain limitations. 20% of ovarian cancer patients are negative or have a low concentration of CA125, and in some benign gynecological diseases Such as endometriosis, benign and malignant tumors of the digestive system, menstrual period, pregnancy and other phys...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12N15/11
CPCC12Q1/6886C12Q2600/158C12Q2600/166C12Q2600/178
Inventor 赵树立张静云袁婷
Owner NANJING FIRST HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com